For every Bingham there will be many more Hardings – why the law of public procurement matters – by a partial and prejudiced public procurement lawyer

2nd February 2021

Like constitutional law and practice, the law and practice of public procurement has recently been exciting.

And this is not a good thing, for also like constitutional law and practice, the law and practice of public procurement should be dull.

But unlike constitutional law and practice – the elements of which like the crown, parliament and the courts are at least well known – the elements of the law and practice of public procurement are not so well known.

Indeed, many commercial and public lawyers can go through their careers and never have to deal with a public procurement issue.

And many commercial companies – all potential government suppliers – will never engage with the public sector.

Public procurement is (usually) a minority interest.

*

But.

Public procurement – that is, in general terms, the purchase by public bodies of goods and services and works (that is, major projects) from the private sector – has become rather politically controversial.

And with Brexit, this public prominence is likely to continue.

So it seemed worthwhile to set out to non-lawyers – and other lawyers with no direct connection with public procurement – to set out some basic points about public procurement, from the subjective perspective of someone who has had some experience in public procurement for twenty years.

*

The starting point, at least in the United Kingdom, is that central government would in principle be able to lawfully buy anything from anyone at any price and on any terms – but for the law of public procurement.

This is because – and here comes some constitutional law mumbo-jumbo – the crown is regarded as a legal person with full capacity.

And just as you and I are able, as natural persons, to enter into contracts, so is the crown.

Of course, it is not Elizabeth Mountbatten-Windsor who is signing contracts for things from toilet rolls to nuclear submarines as part of some extraordinary Waitrose delivery.

But in principle, the crown is able to enter into any contractual obligations it so wishes.

The agreements are, in turn, usually entered into on the crown’s behalf by government departments – usually in the name of the relevant secretary of the state.

(Here it can get complicated, as many secretaries of state are regarded by the law as ‘corporations sole’ that can hold property and so on.)

And so this means that government departments are, in principle, are able to enter into any contractual obligations they so wish.

Apart from central government, there are many other public bodies with a mix of legal forms – from bodies established by royal charter to corporations set up by statute – and these bodies also can, in (very) general terms, enter into contracts as readily as any natural person.

(There used to be many cases where certain transactions were held to be ‘ultra vires’ the powers of local authorities, but legal changes have meant that this is less likely to be the case now.)

And this is the basis of the law of public procurement in the United Kingdom: that but for the law of public procurement, public bodies can in general lawfully enter into transactions freely.

In this way, the law and practice of public procurement should primarily be seen as like the ropes around Lemuel Gulliver or King Kong – preventing public bodies from doing what they otherwise would do.

*

So what are the restraints of public procurement?

In theory, the restraints are of two kinds.

First, there are general principles – at least under the law of the European Union (which has now been adopted as domestic law) and the rules of the World Trade Organisation.

Tenders should be advertised and open to all-comers; selection criteria should be published; public bodies should not discriminate in favour of incumbents and domestic companies; tenderers should be treated equally; procurement exercises should be competitive; there should be transparency; and there should be remedies in the event of unfair treatment.

All very fine and commendable.

And some would say that these principles really should be enough, and that as long as a public body accords with these principles, the public body should be able to be able to procure as it wishes.

Just as, say, an employer can recruit who they wish, as long as they do not discriminate against people with certain characteristics.

But.

The law and practice of public procurement goes further than these general principles – at least for high value procurements.

Much, much further.

This is because, in addition to these general principles, there are detailed procedures prescribed for public authorities to follow.

The theory is that these detailed procedures give practical effect to the general principles, by setting out what can and cannot be done at each of the many stages which a public procurement exercise can be broken down into.

And so behold, for example, the 122 sections and 6 schedules over 133 pages of the Public Contracts Regulations 2015.

Behold also the 178 pages of the European Union directive to which those regulations give effect – with no less than 138 recitals.

So, in practice, public procurement exercises can be long and expensive and complicated and legalistic.

And this, in turn, means that many procurement exercises are dominated by the same few mega-providers with specialist bidding teams – you know which companies, with deliberately bland and meaningless names – that can afford the lost costs of an adverse ratio of losing tenders to winning them.

The laws of public procurement can be seen as a well-intentioned way of opening up the government public procurement market that in fact makes things uncompetitive and inaccessible.

*

There are further problems.

Procurement exercises that start with specifications developed by officials can often mean that providers are expected to provide bespoke (and thereby expensive, unrealistic, risky and untried) products and services rather than commercially off-the-shelf products and services.

And suppliers can exploit their relative power at the final stages of a procurement exercise, or after the contract has been entered into, to remove or vary contractual protections for the public body.

Public bodies do not enforce the contractual rights that they do have.

There is also the the issue of the revolving doors between public bodies and purchasers, with many on both sides knowing each other far better than, say, the officials will know those in other parts of the public body.

And so on.

Many problems.

But.

And this is a big but.

*

As one politician once said of a certain political system, it is the worst form of government, except for all the others.

And the same can be said of public procurement.

Anyone who has been involved in the world of public procurement is alert to the problems.

And most public procurement officials do the best they can with the tools that they have got.

The problem is that, if it was not for the law of public procurement, with all its faults, the practice of public procurement would be worse than it is.

If there were no detailed processes for high-value procurements, then there would be even more of a chumocracy, more corruption, more political rather than commercial decisions, more incumbent bias.

The striking thing about the law and practice of public procurement in the United Kingdom is not that there are abuses but that, relatively speaking, there are so few.

If the law of public procurement was stripped away, even just to general principles, there would be little in practice to prevent a free-for-all with public cash.

The challenge for those, like me, who are critical of the law and practice of public procurement is to work out a better (or less bad) way.

And that is hard.

*

Yet sometimes public procurement exercises do need to be flexible.

The detailed processes sometimes need to be set aside.

The current political controversy over the procurement of vaccines seems to show the merits of the quick decision-making of the United Kingdom over the ponderous and inefficient approach of the European Commission. 

If this is the case, then: hurrah!

But for every Bingham there will be many more Hardings.

For every single successful urgent and informal procurement there will be many more botched and extravagant ones.

And this is because there are huge amounts of cash at stake – and public bodies are reliable payers – and where there is such money, there will be corruption and waste.

*

All large-scale procurement is not easy.

Large procurement exercises in the private sector can also be highly problematic – it is just that they are less likely to feature in the news.

This, in many ways, is not an especially ‘public sector’ problem.

And we should, generally, be glad that the law and practice of public procurement works as well as it does.

Yet, there are ways it could be better.

As this blog recently averred, there is actually no good reason why the terms of public contracts should be confidential – at least in respect of allocations of risk and sanctions for non-performance.

Public bodies should also be more ready to use the powers and sanctions they do have under agreements – as it is, it is rare for any public body to ‘go legal’ in a way that a private sector company would do in a similar way with a similar value contract.

There are grounds for legitimate concern that many high-value, elaborate, time-consuming and cumbersome procurement exercises seem perfectly tailored for the benefit of the tender departments of a certain type of mega-suppler.

In essence: far more transparency, and more realism about how current law and practices are abused.

(Leaving the European Union may also be an opportunity for the United Kingdom to revisit the complexity of our domestic procurement regime – though this opportunity will no doubt not be used well.)

*

What should be exciting in politics is the democratic contest between priorities and policies.

And once a priority has been asserted and a policy adopted, the implementation of that priority and policy should not itself be a political issue. 

This is why public procurement should be dull.

(Similarly, it is rarely a good thing when constitutional law, which sets the agreed parameters of political action, becomes the primary focus of sustained political attention, as this means things are not well in the polity.)

But an awareness of the law and practice of public procurement, and not only of its faults but the greater faults which it prevents, should be part of the stock of civic knowledge of every citizen.

Dull things can still be important things.

*****

The title of this post alludes, of course, to this.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

The one good thing that may come out of the current row about vaccines export controls

1st February 2021

Since 2016 one unfortunate feature of the Brexit policy (or lack of policy) of the United Kingdom has been the disregard for process.

The European Union brought along the tool of process to its negotiations, while the United Kingdom brought bluster and bravado.

The European Union did better in those negotiations than the United Kingdom. 

But.

Process is not the property of the European Union.

Process can be used for the advantage of other parties, depending on the situation.

Or process can protect a weaker party against a misuse of power.

And the United Kingdom was, before Brexit, quite good at using process in its dealings with its then fellow European Union member states and European Union institutions.

The current row over the invocation of Article 16 by the European Union without it properly having followed the correct (or indeed any) process shows how important it is to hold the European Union to following an agreed process.

Process can matter, a lot.

And process can work to the advantage of the United Kingdom too.

As the United Kingdom develops its post-Brexit relationship with the European Union, through the joint institutions and agreed procedures of the trade and cooperation agreement, the good and thoughtful use of process could become an advantage in respect of the European Union.

The United Kingdom does not have to persist with the loud crashes, bangs and wallops of the Brexit era.

Playing the European Union at its own game, and winning, is also possible.

(Even if the wins are cloaked under the cover of ‘jointly beneficial outcomes’ and other such comforting language.)

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.

What the AstraZeneca agreement actually says

31st January 2021

Was AstraZeneca under a firm obligation to supply the vaccine to the European Commission or was it only under an obligation to use its best efforts?

Only the agreement would tell us for certain.

And a few days ago it did not look like that politically controversial vaccine agreement between the European Commission and AstraZeneca was going to be published.

So, in that circumstance, this blog had a post which, on the basis of public domain information then available – including a published (and redacted) contract with another supplier – sought to put together what might be said about the AstraZeneca agreement.

That post is now superseded, for the AstraZeneca agreement has now been published, though in redacted form.

What this now-published agreement tells us, even more than before, is that AstraZeneca may have been wronged in the political row with the European Commission.

For, just as the European Commission was wrong in invoking article 16 (though that was promptly reversed), it looks as if it was also wrong in how it publicly characterised the contractual obligations of AstraZeneca.

*

Before we get going, some assumptions and provisos.

The AstraZeneca agreement is under the law of Belgium and is subject to the jurisdiction of the courts of Brussels – and I am not a Belgian lawyer.

This means there will be law relevant to the understanding of the agreement of which I will be unaware.

But as I am not providing legal advice but instead mere commentary on an English language legal instrument in the public domain, the fact that the document is under foreign law is not an absolute barrier – though please bear in mind this limitation.

The agreement is also redacted, and there may also be other legal instruments or texts that may be relevant, and so this post is on the basis of the information which is available at the time of writing.

I am also aware that there are versions of the agreement on the internet which purport to show the redacted text but I have not looked at any of these and I respect the confidentiality of the parties: this post is on the basis of the text published by the European Commission.

What follows is an account of what the AstraZeneca agreement says by an English legal commentator with some experience as a lawyer in commercial contracts and public procurement matters.

*

First, the parties.

The agreement is between the European Commission, acting on behalf of European Union member states, and AstraZeneca AB, incorporated in Sweden.

That this is the AstraZeneca entity that is party to the agreement may be significant, for (all other things being equal) only that entity will be bound by obligations on AstraZeneca in the agreement – and not any other AstraZeneca entity.

As we will see, this possible distinction may be important (or at least of interest) depending on which AstraZeneca entity is party to the prior agreement for the supply of the vaccine in the United Kingdom.

*

Moving on from the parties, we come next to the recitals.

Recitals are curious things in legal instruments – and tend to be far more popular (and numerous) in continental Europe than in England.

(Some European Union legal instruments have recitals that go on for longer than the operative provisions.)

The notion is that a recital does not (or should not) create a legal obligation in and of itself.

Instead, a recital should tell those considering the instrument what the background is to the document and thereby it gives a steer to how the operative provisions should be construed.

Recitals are thereby (or should be) an aid to construction and interpretation of a legal instrument.

(That said, in twenty years of experience of practical commercial law, I have seen recitals used for all sorts of naughty purposes.)

The key recitals in the AstraZeneca agreement are the following:

These recitals set out the shared understanding of the European Commission and AstraZeneca as at the time of the agreement (which was signed by both parties on 27 August 2020).

A breach of a recital – that is, if a recital is not factually true – does not (at least under English law) trigger any automatic remedy.

But a recital can have effect when it comes to construing the effects of other provisions.

The first of the three quoted recitals is interesting in that it shows the European Commission is already aware that AstraZeneca is scaling up its capacity for the broadest possible availability, separately from this agreement.

The second quoted recital then expressly affirms that this agreement is only ‘part’ of that scale-up.

And the second quoted recital introduces the phrase that has become famous as part of the current political controversy: ‘Best Reasonable Efforts’.

In particular, the recital records that AstraZeneca is committed to using ‘Best Reasonable Efforts’ to build capacity to manufacture 300 million ‘initial’ doses.  

The third quoted recital then says the supply of those ‘initial’ doses will be in accordance with the terms of the agreement.

(As these are only recitals, not that much – or perhaps anything – can be made of the second quoted recital not referring to ‘according to the terms of the agreement’ but the third quoted recital then doing so, but it is a curious omission.)

*

So much for the recitals.

But before we go to the operative obligations, we need to look at the definitions and at one definition in particular: ‘Best Reasonable Efforts’.

Here, unlike in English law agreements which tend to leave ‘best endeavours’ and ‘reasonable endeavours’ to a court to sort out (though I did once catch one naughty ‘Magic Circle’ law firm trying to expressly define in a contract the more onerous ‘best endeavours’ to mean the less onerous ‘reasonable endeavours’), the parties in this agreement have agreed a definition of ‘Best Reasonable Efforts’.

Indeed, like New York, so enamoured are the parties of the concept, the parties have defined the term twice.

There are ‘Best Reasonable Efforts’ for the commission and ‘Best Reasonable Efforts’ for AstraZeneca.

As we are concerned with the supply obligations of AstraZeneca, we need to know what the term means for them:

Here we need to remember that a definition is only a definition, and that the important thing is how the definition is employed in an operative clause.

But when we do see the term in an operative clause, all of this definition will be applicable.

And so there is a significant difference between an absolute obligation (‘[x] shall do [y]’) and a qualified obligation ‘[x] shall use Best Reasonable Efforts to do [y]’ – for the latter comes with all the baggage of the defined term.

*

Now come the operative clauses.

This being a bilateral supply agreement, the primary obligations will be for one party to supply a thing, and for the other party to pay for it.

In very (very) general terms, many of the other provisions of the agreement will be of secondary importance to these two primary obligations.

This post is not concerned with the payment obligations, many of which are in any case redacted, and so we will look at the supply obligations.

These mainly are in article 5.

The primary obligation of the supplier under this agreement is to do two things: to manufacture (so that the vaccine is ready for distribution) and to deliver.

And, in respect of the initial doses, this dual obligation is in article 5.1:

We can also see that this provision makes both the manufacturing-ready-for-distribution and delivery obligations for the initial doses of the vaccine subject to ‘Best Reasonable Efforts’.

(Articles 5.2 and 5.3 then deal with optional orders for further and additional doses.)

But then there is a further clause – which sadly warrants an Alan Hansen wince at its awkward drafting.

Article 5.4 provides:

Is this also a primary supply obligation?

Perhaps it is, and article 5.1 goes only to distribution and delivery, but it seems to me that the intention is that article 5.4 deals only with the location of the manufacturing (hence (a) the heading of article 5.4, though headings usually are not to be used for interpreting contracts, and (b) the text in the article which follows ‘provided’) – rather than it being the primary manufacturing obligation itself.

And the placing of the reference in that article to the United Kingdom is also odd, though this was probably a late amendment to make sure that the provision was Brexit-proof.

But for the purpose of this post, it does not really matter, as this obligation too is subject to ‘Best Reasonable Efforts’.

*

But, as the jurist Jimmy Cricket would aver, there is more.

If we now go down to article 13 we will see the representations and warranties of AstraZeneca:

And we can see at article 13(1)(e) what may seem to be a relevant promise by AstraZeneca.

Did AstraZeneca fail to fulfil its contractual obligations to the European Union by reason of conflict with obligations to third parties?

Did such obligations to third parties impede AstraZeneca’s performance of its obligations under this agreement?

A breach of article 13(1)(e) by AstraZeneca would be legally consequential – this is not just a recital – and (at least under English law) a breach would entitle the European Commission to compensation, if it could show that it caused damage, or even to rescind the agreement.

But it is not clear that the fact that AstraZeneca did have a prior agreement in respect of the United Kingdom such that it would mean that AstraZeneca was in breach of article 13(1)(e).

Article 13(1)(e) does not say that AstraZeneca promises to not have any other such obligations but that those obligations will not conflict with this agreement or impede performance of the obligations under this agreement.

And the relevant obligations under this agreement are, as defined, simply to use ‘Best Reasonable Efforts’ – so the other obligations would have to conflict with or impede not some absolute obligation, but only an obligation to use ‘Best Reasonable Efforts’.

Furthermore, and as we have already seen with the recitals, the European Commission expressly acknowledged that AstraZeneca was scaling-up manufacture generally, and that only part of this was for the European Commission.

That AstraZeneca had a prior agreement in respect of the United Kingdom was also well-publicised and it cannot be seriously posited as something unknown by and unforeseen to the commission.

Indeed, AstraZeneca was in a position to scale-up and so on because of this prior agreement.

In all these circumstances, it would seem to me to be difficult for the European Commission to rely on article 13(1)(e), and even if it could, it is not clear where that would get the commission.

And, of course, there would also be the possible difficulty that the Swedish AstraZeneca entity that accepted the burden of article 13(1)(e) is not even the AstraZeneca entity that has entered into any obligations in respect of the United Kingdom.

*

So, we can now go back to Wednesday 27th January 2021, when the relevant European Commissioner said:

‘The view that [AstraZeneca] is not obliged to deliver because we signed a ‘best effort’ agreement is neither correct nor is it acceptable.’

In view of what that agreement actually says – recitals, definitions, primary obligations, warranties, representations, and so on – there is reason to believe that this statement by the commissioner was incorrect and misleading.

As long as AstraZeneca fulfilled the definition of ‘Best Reasonable Efforts’ in respect of its obligations under article 5(1) of the agreement, then AstraZeneca has performed its side of the bargain.

*****

If you value this free-to-read and independent legal and policy commentary please do support through the Paypal box above, or become a Patreon subscriber.

Each post takes time, effort, and opportunity cost.

Suggested donation of any amount as a one-off, or of £4.50 upwards on a monthly profile.

This law and policy blog provides a daily post commenting on and contextualising topical law and policy matters – each post is usually published at about 9.30am UK time – though some special posts are published later.

*****

You can also subscribe for each post to be sent by email at the subscription box above (on an internet browser) or on a pulldown list (on mobile).

*****

Comments Policy

This blog enjoys a high standard of comments, many of which are better and more interesting than the posts.

Comments are welcome, but they are pre-moderated.

Comments will not be published if irksome.